RT Journal Article
SR Electronic
T1 Distorted TCR repertoires define multisystem inflammatory syndrome in children
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.12.21255098
DO 10.1101/2021.04.12.21255098
A1 Malik, Amna
A1 Tóth, Eszter N.
A1 Teng, Michelle S.
A1 Hurst, Jacob
A1 Watt, Eleanor
A1 Wise, Lauren
A1 Kent, Natalie
A1 Bartram, Jack
A1 Grandjean, Louis
A1 Dominguez-Villar, Margarita
A1 Adams, Stuart
A1 Cooper, Nichola
YR 2021
UL http://medrxiv.org/content/early/2021/04/15/2021.04.12.21255098.abstract
AB While the majority of children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) display mild or no symptoms, rare individuals develop severe disease presenting with multisystem inflammatory syndrome (MIS-C). The reason for variable clinical manifestations is not understood. Here, we carried out TCR sequencing and conducted comparative analyses of TCR repertoires between children with severe (n=12) or mild (n=8) COVID-19. We compared these repertoires with unexposed individuals (samples collected pre-COVID-19 pandemic: n=8) and with the Adaptive Biotechnologies MIRA dataset, which includes over 135,000 high-confidence SARS-CoV-2-specific TCRs. We show that the repertoires of severely ill children are characterised by the expansion of TRBV11-2 chains with high junctional and CDR3 diversity. Moreover, the CDR3 sequences of TRBV11-2 clones shift away from SARS-CoV-2 specific T cell clones, resulting in distorted TCR repertoires. In conclusion, our study reports that CDR3-independent expansion of TRBV11-2+ cells, lacking SARS-CoV-2 specificity, defines severity of disease in children.Competing Interest StatementE.N.T., M.S.T. and J.H. have a financial interest in Etcembly Ltd.Funding StatementN.C and M.D.V. are partially funded by Imperial College NIHR BRC. A.M. is funded by the Jon Moulton Charity.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was done in accordance with The Multi Centre Research Ethics Committee in Wales guidelines MREC Wales reference 06/Q0508/16 Approval was given by: NHS Health Research Authority, London Bloomsbury Research Ethics Committee, HRA RES Centre Manchester, Barlow House 3rd Floor 4 Minshull Street, Manchester M1 3DZ. Study title: Development of Diagnostic Tests for Primary Immunodeficiency REC reference: 06/Q0508/16All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatasets generated and analyzed in this study will be made available through Gene Expression Omnibus (GEO).